Company intelligence / Profile preview

Ideal Medical Technologies

Asheville, North Carolina, United Statesidealmedtech.com ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Ideal Medical Technologies has developed the FUSION system—an AI-powered closed-loop artificial pancreas for ICU and hospital use. The device automates blood glucose control by continuously monitoring levels and adjusting insulin/dextrose delivery. In first-in-human safety studies completed in 2023, the system demonstrated strong efficacy with an average percent time in range (70–180 mg/dL) of 87.8% and minimal hypoglycemia (<70 mg/dL at 0.2%). The FDA granted Breakthrough Device status to FUSION

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Velentium (OEM/software compliance partner)Emory University Hospital (clinical trial site)

Beyond the preview

Go deeper on Ideal Medical Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ideal Medical Technologies.

Explore the full profile